SC
ALDR

Samlyn Capital’s Alder Biopharmaceuticals ALDR Stock Holding History

Samlyn Capital’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-798,873
Closed -$15.1M – 147
2019
Q3 		$15.1M Sell
798,873
-2,718,983
-77% -$31.1M 0.37% 68
2019
Q2 		$41.4M Buy
3,517,856
+331,873
+10% +$4.02M 0.87% 44
2019
Q1 		$43.5M Buy
3,185,983
+367,195
+13% +$4.76M 1.03% 38
2018
Q4 		$28.9M Buy
2,818,788
+904,098
+47% +$11.6M 0.69% 45
2018
Q3 		$31.9M Buy
1,914,690
+279,655
+17% +$5.05M 0.72% 56
2018
Q2 		$25.8M Buy
1,635,035
+1,071,998
+190% +$16.3M 0.6% 61
2018
Q1 		$7.15M Buy
+563,037
New +$8.14M 0.16% 96
2017
Q2 		– Sell
-181,143
Closed -$3.77M – 165
2017
Q1 		$3.77M Buy
181,143
+1,143
+0.6% +$25.3K 0.09% 130
2016
Q4 		$3.74M Buy
+180,000
New +$4.68M 0.08% 116

Samlyn Capital's ALDR Position: Q4 2019 in Review

Samlyn Capital sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 798,873 shares — an estimated $15.1M sold.

Samlyn Capital first reported a position in ALDR in Q4 2016 and held it in 9 quarters. The position peaked at $43.5M in Q1 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

  • Samlyn Capital reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Samlyn Capital sold 798,873 Alder Biopharmaceuticals shares in Q4 2019, an estimated $15.1M.
  • Samlyn Capital first reported a position in Alder Biopharmaceuticals in Q4 2016 and held it in 9 quarters.
  • Samlyn Capital's Alder Biopharmaceuticals position peaked at $43.5M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Samlyn Capital's 13F filing for Q4 2019, filed 14 Feb 2020.